Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2023 Results of the safety and efficacy of treatment with mitapivat in patients with SCD from the 1-year fixed-dose extension period , presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Jun 2023 Results (n=9) assessing pre-specified safety and efficacy data of the 1-year fixed-dose extension period (FDEP) ofmitapivat treatment in subjects with SCD, presented at the 28th Congress of the European Haematology Association.
11 May 2023 According to an Agios Pharmaceuticals Media Release, data from this trial will be presented at the 2023 European Hematology Association (EHA) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com